非酒精性脂肪性肝病高危人群:监测与防治

doi:10.3969/j.issn.1672-5069.2020.05.002

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (5): 612-614.doi: 10.3969/j.issn.1672-5069.2020.05.002

非酒精性脂肪性肝病高危人群:监测与防治

李俊缨, 周玲, 陈金军

511340 广州市南方医科大学南方医院增城分院(李俊缨,陈金军);
南方医院(周玲)

出版日期:2020-09-10 发布日期:2020-09-11
通讯作者: 陈金军,E-mail:chjj@smu.edu.cn
作者简介:李俊缨:女,27岁,南方医科大学传染病学硕士。主要从事非酒精性脂肪性肝病诊断和微创减重手术治疗临床研究。E-mail:2292921780@qq.com
基金资助:
科技部病毒性肝炎及艾滋病等传染病重大专项 (编号:2018ZX10723203);珠江人才计划本土创新团队项目(编号:2017BT01S131)

Surveillance and management of individuals with high risk of NAFLD

Li Junying, Zhou Ling, Chen Jinjun

Department of Liver Diseases, Zengcheng Branch, Nanfang Hospital, Guangzhou 510515, Guangdong Province, China

Online:2020-09-10 Published:2020-09-11

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 高危人群, 防治 , ,

Key words: Non-alcoholic fatty liver diseases, High risk, Surveillance and management

李俊缨, 周玲, 陈金军. 非酒精性脂肪性肝病高危人群:监测与防治[J]. 实用肝脏病杂志, 2020, 23(5): 612-614.

Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD[J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.

[1] CarlssonB, Lindén D, Brolén G, et al. The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2020,51(12):1305-1320.
[2] AlexanderM, Loomis AK, Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ, 2019,367:l5367.
[3] Lonardo A, Bellentani S, KArgo C, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis, 2015,47(12):997-1006.
[4] Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol, 2015,13(4):643-654.
[5] Cowman S. Commentary on forensic and non-forensic psychiatric nursing skills and competencies for psychopathic and personality disordered patients. J Clin Nurs, 2014,23(7-8):1170-1171.
[6] Lebeau PF, Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep, 2019, 1(6):418-429.
[7] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol, 2019,71(4):793-801.
[8] Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology, 2019,69(1):64-75.
[9] Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017,66(6):2055-2065.
[10] Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int, 2019,13(6):674-687.
[11] Barata L, Feitosa MF, Bielak LF, et al. Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatol Commun, 2019,3(7):894-907.
[12] Xia MF, Chen LY, Wu L, et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: The Shanghai Changfeng study. Aliment Pharmacol Ther, 2019,50(6):684-695.
[13] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol, 2012,56(5):1145-1151.
[14] Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2018,33(6):1277-1285.
[15] Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer, 2013,108:222-228.
[16] Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for theperiod 2016-2030. J Hepatol, 2018,69(4):896-904.
[17] Hannah WN Jr, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2016,64(6):2234-2243.
[18] Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.J Gastroenterol. 2018,53(2):181-196.
[19] 李俊缨,熊鸣,张继平,等.非酒精性脂肪性肝炎相关肝硬化的诊断和治疗进展. 肝脏. 2019,24(10):1008-1704.
[20] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011,53:1020-1022.
[21] Goldner D, Lavine JE. NAFLD in children: unique considerations and challenges. Gastroenterology, 2020,158(7):1967-1983.
[22] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol, 2012,56:1145-1151.
[23] Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017,377(21):2063-2072.
[24] Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related, Child-Pugh A cirrhosis. Clin Gastroenterol Hepatol, 2020,S1542-3565(20)30633-30639.
[25] Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int, 2016,36:317-324.
[26] Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol, 2013,59:536-542.
[27] Weiss CR, Abiola GO, Fischman AM, et al. Bariatric embolization of arteries for the treatment of obesity (BEAT obesity) trial: results at 1 Year.Radiology, 2019,291(3):792-800.

非酒精性脂肪性肝病高危人群:监测与防治

Surveillance and management of individuals with high risk of NAFLD

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张伟, 施军平. 创建MAFLD防治新模式,合力推进分层全程管理[J]. 实用肝脏病杂志, 2020, 23(5): 609-611.
[2]	叶俊钊, 钟碧慧. 非酒精性脂肪性肝病合并代谢并发症患者规范治疗与管理[J]. 实用肝脏病杂志, 2020, 23(5): 615-618.
[3]	宋怀宇. 健康教育和健康促进在脂肪肝防治中的作用[J]. 实用肝脏病杂志, 2020, 23(5): 619-621.
[4]	吴刚, 陈训军, 张万里, 李芬. 二氢姜黄素体外处理BRL-3A细胞对细胞凋亡通路的影响[J]. 实用肝脏病杂志, 2020, 23(5): 622-625.
[5]	王雨, 王楠, 刘媛媛, 李永勤, 王巧侠, 付建军. 草质素对非酒精性脂肪性肝炎大鼠肝脂肪变和肝内氧化应激的影响[J]. 实用肝脏病杂志, 2020, 23(5): 626-629.
[6]	余姣, 陈姬秀, 薛建亚, 张彩虹. 血清HBsAg阳性孕妇血清细胞因子水平对HBV母婴传播的影响[J]. 实用肝脏病杂志, 2020, 23(5): 630-633.
[7]	方奕, 陈毅雄, 裴冬萍, 操银针. 恩替卡韦联合复方嗜酸乳杆菌治疗CHB合并NAFLD患者疗效及其对血清相关酶系的影响[J]. 实用肝脏病杂志, 2020, 23(5): 634-637.
[8]	吴雄飞, 方利娟, 陈艳. 替诺福韦联合干扰素-α治疗HBeAg阳性慢性乙型肝炎患者疗效及其血清细胞因子水平变化[J]. 实用肝脏病杂志, 2020, 23(5): 638-641.
[9]	张浩, 常建东, 陈小燕. 超声弹性成像结合血清学指标诊断慢性乙型肝炎患者肝纤维化价值评价[J]. 实用肝脏病杂志, 2020, 23(5): 642-645.
[10]	周长雄, 于文虎, 金笛. 艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效初步观察[J]. 实用肝脏病杂志, 2020, 23(5): 646-649.
[11]	刘松涛, 李娟, 于红卫, 侯维, 胡中杰. 9例以肝功能异常起病的恶性淋巴瘤患者临床特征分析[J]. 实用肝脏病杂志, 2020, 23(5): 650-653.
[12]	江守伟, 金坤, 沈强, 韩华, 刘磊, 杨云, 杨田军, 潘爱军, 李磊. 重型和危重型新型冠状病毒肺炎患者肝功能损害回顾性分析[J]. 实用肝脏病杂志, 2020, 23(5): 654-657.
[13]	陈丽丽, 符茂雄, 刘正金, 方其超, 张茂. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2020, 23(5): 658-661.
[14]	卢泳宇, 刘昌江, 黄帅. 水飞蓟宾葡甲胺联合胆宁片治疗酒精性肝炎患者疗效及其对血脂和氧化应激指标的影响[J]. 实用肝脏病杂志, 2020, 23(5): 662-665.
[15]	吴杰, 谢丽响, 修金. 多烯磷脂酰胆碱联合双环醇治疗胃癌化疗导致的药物性肝损伤患者疗效及其对血清细胞因子和氧化应激指标水平的影响[J]. 实用肝脏病杂志, 2020, 23(5): 666-669.